Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PERSEUS

Financiado

Cerrado

2D Material Based Multiple Oncotherapy Against Metastatic Disease Using a Radica...

2D Material Based Multiple Oncotherapy Against Metastatic Disease Using a Radically New Computed Tomography Approach PERSEUS intends to implement a novel nanotechnology-based cancer therapy for deep-seated clinically unmanageable, drug-resistant and metastatic tumours. Practical use of nanotechnology in clinical cancer care is still in its infan... ver más

28/02/2027

Líder desconocido

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto Líder desconocido

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-12-16

HORIZON-EIC-2022-PATHFINDEROPEN-01-01: EIC Pathfinder Open 2022 Scope:You should apply to this call if you are looking for support from EIC Pathfinder Open to reali...

I+D

Cerrada

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 50 meses Fecha Inicio: 2022-12-16
Fecha Fin: 2027-02-28

Líder del proyecto Líder desconocido

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto PERSEUS intends to implement a novel nanotechnology-based cancer therapy for deep-seated clinically unmanageable, drug-resistant and metastatic tumours. Practical use of nanotechnology in clinical cancer care is still in its infancy with a full potential yet to be realized. The therapy is based on a novel nano-system (NS) made of multifunctional 2D layered nanocrystals. The NS enables, under activation by computed tomography (CT), an effective multimodal therapy with minimal or no adverse effects. This novel paradigm uses CT not to eradicate cancer, but to trigger and to image the NS that locally activates non-mutagenic oncotherapies. The therapies delivered are excited by the conversion of low energy X-rays (i.e., CT) into heat, reactive oxygen species and radiosensitizing agents. X-ray irradiation can also induce immunogenic cell death with the exposure or release of neo-antigens to trigger an anti-cancer immune response. The use of X-rays makes it possible to reach deep-seated tumours that are inaccessible by visible or near-infrared light-based therapies. In other words, CT is the spark that lights the match. This is a radical vision for an ambitious and high-risk project. The current proposal targets a range of cancer types including metastatic triple negative breast cancer, hepatocellular carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma. The NS is biocompatible and also totally inactive in absence of CT radiation, i.e. the NS becomes active only where the CT beam is delivered so minimizing side effects at distal sites. The therapy is agnostic to the type of cancer and to gender incidence because it doesn't affect the body biochemistry. This is a second change of paradigm. PERSEUS vision is pursued by a multidisciplinary team composed of physicists, chemists, chemical engineers, biologists, physicians, pharmacologists and radiologists working together to develop an innovative nanotechnological approach to address unmet clinical needs.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores